- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00823940
A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects
July 5, 2017 updated by: GlaxoSmithKline
A Single-blind, Randomized, Placebo Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Healthy Normal Subjects.
The study will investigate whether GSK1362885 is safe and well-tolerated when administered to normal healthy subjects.
The study will also measure blood levels of the study drug to determine how the body processes the drug (pharmacokinetics) and what effects the drug has on the body (pharmacodynamics).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
GSK1362885 is a glycogen phosphorylase inhibitor that is targeted as a treatment for Type 2 Diabetes Mellitus by reducing hepatic glucose output.
This study will investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics when single doses of GSK1362885 are administered to healthy volunteers.
A glucagon challenge test will be used to stimulate hepatic glucose output in order to evaluate liver glycogen phosphorylase inhibition by GSK1362885.
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- Male or female between 18 and 55 years of age, inclusive, at the time of signing the informed consent.
- A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea
- BMI within the range 20.0 to 31.9 kg/m2 (inclusive).
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Normal cardiac function and ECG parameters, as per protocol.
- No significant rhythm abnormalities in the Screening Holter ECG recording.
Exclusion Criteria:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- The subject has a positive pre-study drug/alcohol screen. A minimum list of tobacco/drugs that will be screened include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks/week for men or >7 drinks/week for women.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- History of glycogen storage disease
- Unable or unwilling to abstain from:
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices for 7 days prior to the first dose of study medication until the final post-dose assessment at each treatment level.
- Caffeine-or xanthine-containing products for 24 hours prior to dosing until the final post-dose assessment at each treatment level.
- Use of illicit drugs
- Alcohol for 24 hours prior to dosing until final post-dose assessment at each treatment level.
- Strenuous exercise for 48 hours prior to each blood collection for clinical laboratory tests. Subjects may participate in light recreational activities during studies (e.g., watch television, read).
- History of uncorrected thyroid dysfunction or an abnormal thyroid function test assessed by TSH and free T4 at screening
- Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
- Lactating females.
- History of any gastrointestinal or hepatic conditions that could impact absorption of the investigational compound.
- Significant ECG abnormalities as defined per protocol
- Resting systolic blood pressure < 80 mmHg or > 150 or diastolic blood pressure < 60 mmHg or > 90 mmHg at screening. Resting heart rate is outside the range of 45 to 100 bpm.
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody.
- A positive test for HIV antibody.
- A fasting triglyceride level >400mg/dL (4.45mmol/L).
- Anemia defined by hemoglobin concentration <11.0g/dL for males or <10.0g/lL for females.
- Significant renal disease as manifested by one or more of the following:
- Creatinine clearance <80 mL/min. (estimated from serum creatinine (SCr) and demographic data using the MDRD calculation):
- Urine protein/creatinine (mg/mg) ratio >2.5; or urine albumin concentration >300 g/mg of creatinine.
- Known loss of a kidney either by surgical ablation, injury, or disease
- Subjects with values outside the specified ranges for the following key clinical laboratory tests at Screening and at readmission for each treatment period. Laboratory tests may be repeated once to confirm eligibility prior to dosing:
- Liver function tests: ALT, Direct Bilirubin, or Albumin more than 10% outside the normal reference range (<0.9 x LLN or >1.1 x ULN)
- Electrolytes: Sodium more than +/- 5mEq/L outside the normal reference range, potassium or Calcium more than 10% outside the normal reference range (<0.9 x LLN or >1.1.x ULN).
- Metabolic: Glucose more than 10% outside the normal reference range (<0.9 x LLN or >1.1 x ULN), Total Cholesterol >240mg/dl.
- Muscle: CPK >2 x ULN.
- Hematology: Hemoglobin, WBC Neutrophils, or Platelets more than 10% outside the normal reference range (<0.9 x LLN or >1.1. x ULN).
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) is prohibited from 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication until the final post-dose assessment, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Unable or unwilling to discontinue aspirin use during the study. Subjects who are taking low-dose aspirin for cardiovascular prophylaxis (81 mg or less) are eligible to participate in the study, but the aspirin must be discontinued from Screening through the Follow-up visit.
Other
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- As a result of the medical interview, physical examination, or screening investigations, the investigator considers the subject unfit for the study.
- Subject is either an immediate family member of a participating investigator, study coordinator, employee of an investigator; or is a member of the staff conducting the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Cohort A1
Dose escalation: 5 - 100mg and placebo in 4 planned doses
|
5 - 100mg of GSK1362885 or placebo
100 - 600mg or placebo
|
Placebo Comparator: Cohort A2
Dose escalation: 100-600mg and placebo in 4 planned doses
|
5 - 100mg of GSK1362885 or placebo
100 - 600mg or placebo
|
Other: Cohort B1
Glucagon challenge test
|
0.5mg IV bolus
|
Active Comparator: Cohort B3
Glucagon challenge test + selected dose of GSK1362885
|
0.5mg Glucagon IV bolus + selected dose of GSK1362885
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability assessments including adverse events, clinical laboratory tests, electrocardiogram (ECG) and vital signs
Time Frame: During the duration of study participation (from 2 days up to 5 weeks)
|
During the duration of study participation (from 2 days up to 5 weeks)
|
Pharmacokinetic parameters: AUC, Cmax, Tmax, t1/2, tlag, Cl/F, and V/F
Time Frame: 24 - 48 hours following each dose
|
24 - 48 hours following each dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameters to assess dose proportionality and food effect
Time Frame: 24 - 48 hours following each dose
|
24 - 48 hours following each dose
|
Pharmacodynamic parameters may include change from baseline in glucose, insulin, C-peptide and AUC following administration of IV glucagon in a standardized GC test with and without prior administration of GSK1362885
Time Frame: 24 - 48 hours following each dose
|
24 - 48 hours following each dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 13, 2009
Primary Completion (Actual)
April 27, 2009
Study Completion (Actual)
April 27, 2009
Study Registration Dates
First Submitted
January 15, 2009
First Submitted That Met QC Criteria
January 15, 2009
First Posted (Estimate)
January 16, 2009
Study Record Updates
Last Update Posted (Actual)
July 7, 2017
Last Update Submitted That Met QC Criteria
July 5, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 111497
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Dataset Specification
Information identifier: 111497Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 111497Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 111497Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 111497Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 111497Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 111497Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 111497Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on GSK1362885
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States